<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008575</url>
  </required_header>
  <id_info>
    <org_study_id>CD33 CAR NK-AML</org_study_id>
    <nct_id>NCT05008575</nct_id>
  </id_info>
  <brief_title>Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Phase I Study to Evaluate the Safety and Effectiveness of Anti-CD33 CAR NK Cell Therapy in Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CAR technology has been used in T cell therapy and gets great success in treating&#xD;
      hematological diseases. Following models of CAR T cells, CAR NK cell therapy has been one hot&#xD;
      point. For myeloid malignancies, CD33 is widely expressed. Targeting CD33 surface antigens by&#xD;
      CAR NK cells provides an off-the-shelf immune cell therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Remission Rate (ORR)</measure>
    <time_frame>4 weeks after infusion</time_frame>
    <description>Assessment of morphologic complete remission (CR), complete remission with incomplete recovery of counts (CRi), no residual disease as analyzed by flow cytometry analysis, and molecular remission by molecular studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of participants with dose limiting toxicity (DLT)</measure>
    <time_frame>within 4 weeks after infusion</time_frame>
    <description>To characterize the safety, tolerability of Anti-CD33 CAR NK cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 2 years after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 2 years after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>up to 2 years after infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>antiCD33 CAR NK cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After preconditioning with chemotherapy, the antiCD33 CAR NK cells will be evaluated</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-CD33 CAR NK cells</intervention_name>
    <description>1-3×10^6 /KG, 3-6×10^6 /KG, 0.6-1.2×10^7/KG Treatment follows a lymphodepletion</description>
    <arm_group_label>antiCD33 CAR NK cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>recommendation: 30mg/m2 (D-5~D-3),determined by tumor burden at baseline.</description>
    <arm_group_label>antiCD33 CAR NK cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytoxan</intervention_name>
    <description>recommendation: 300-500mg/m2 (D-5~D-3),determined by tumor burden at baseline.</description>
    <arm_group_label>antiCD33 CAR NK cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ECOG performance status score ≤ 2.&#xD;
&#xD;
          2. Life expectancy ≥ 12 weeks from the time of enrollment.&#xD;
&#xD;
          3. Disease status at the time of enrollment: -Patients with AML (except M3) who have not&#xD;
             achieved complete remission after standard chemotherapy regimens; -Not suitable or&#xD;
             unconditional for allogeneic hematopoietic stem cell transplantation; -Patients with&#xD;
             recurrent acute myeloid leukemia after autologous hematopoietic stem cell&#xD;
             transplantation without active graft-versus-host disease (GVHD).&#xD;
&#xD;
          4. CD33 expression must be detected on greater than 50% of the malignant cells by&#xD;
             immunohistochemistry or greater than 80% by flow cytometry.&#xD;
&#xD;
          5. Adequate main organ function as assessed by the following laboratory requirements:&#xD;
             creatinine ≤ 2.5 × upper limit of normal, cardiac ejection fraction ≥ 40%, oxygen&#xD;
             saturation ≥ 90%, total bilirubin ≤ 3 × upper limit of normal, aspartate&#xD;
             aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal,&#xD;
             Hgb≥80g/L.&#xD;
&#xD;
          6. Without history of accepting anti-cancer therapy, including chemotherapy,&#xD;
             radiotherapy, immunotherapy (immune suppressive drugs or corticosteroid treatment)&#xD;
             within 4 weeks of screening.&#xD;
&#xD;
          7. Women of child-bearing age must have evidence of negative pregnancy test.&#xD;
&#xD;
          8. Subjects of reproductive potential must agree to use acceptable birth control methods&#xD;
             within 1 year after treatment, as described in protocol.&#xD;
&#xD;
          9. After discussion by the expert group, the patient's condition was analyzed and&#xD;
             combined with the general physical condition of the patient, the benefit of&#xD;
             participating in the clinical trial was greater than the risk.&#xD;
&#xD;
         10. All participants must have the ability to understand and willingness to sign a written&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of acute promyelocytic leukemia (APL M3): t(15;17)(q22;q12); (promyelocytic&#xD;
             leukemia [PML]/retinoic acid receptor [RAR] alpha [a]) and variants excluded.&#xD;
&#xD;
          2. Active acute or chronic GVHD or requirement of immunosuppressant medications for GVHD&#xD;
             within 4 weeks of enrollment.&#xD;
&#xD;
          3. Have been diagnosed with or treated other malignant tumors other than AML within 5&#xD;
             years before screening, except for the following conditions: participants with&#xD;
             adequately treated cervical carcinoma in situ, basal cell or squamous cell skin&#xD;
             cancer; or received radical treatment Local prostate cancer, ductal carcinoma in situ.&#xD;
&#xD;
          4. There are serious systemic diseases: New York Heart Association (NYHA) stage III or IV&#xD;
             congestive heart failure; cerebrovascular accident or myocardial infarction or&#xD;
             hemodynamic instability caused by arrhythmia within 6 months before signing the&#xD;
             informed consent; impaired cardiac function (LVEF&lt;50%) assessed by echocardiographic&#xD;
             scan.&#xD;
&#xD;
          5. Sever illness or medical condition, which would not permit the patient to be managed&#xD;
             according to the protocol, including active uncontrolled infection.&#xD;
&#xD;
          6. Pregnant or lactating women.&#xD;
&#xD;
          7. Subjects with radiologically-detected CNS chloromas or CNS 3 disease (presence of ≥&#xD;
             5/μL white blood cells (WBCs) in cerebral spinal fluid (CSF) and cytospin positive for&#xD;
             blasts [in the absence of a traumatic lumbar puncture] and/or clinical signs of CNS&#xD;
             leukemia such as a cranial nerve palsy from active disease). Subjects with adequately&#xD;
             treated CNS leukemia are eligible.&#xD;
&#xD;
          8. Human immunodeficiency virus (HIV) seropositivity; hepatitis B surface antigen is&#xD;
             positive or HBV DNA is higher than the detection limit of the analysis method;&#xD;
             hepatitis C antibody is positive or HCV RNA is higher than the detection limit of the&#xD;
             analysis method; syphilis antibody and syphilis rapid plasma reagin are positive; CMV&#xD;
             DNA is positive.&#xD;
&#xD;
          9. Patients who suffer from allergies for any cytokines or antibodies.&#xD;
&#xD;
         10. Contraindications for fludarabine or cyclophosphamide treatment.&#xD;
&#xD;
         11. Receiving corticosteroids at &gt;20 mg daily prednisone dose or equivalent.&#xD;
&#xD;
         12. Drug abuse and addiction.&#xD;
&#xD;
         13. History of mental disorders.&#xD;
&#xD;
         14. Other patients that researchers considered unsuitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xi zhang, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, Xinqiao Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xi zhang, MD/PhD</last_name>
    <phone>13808310064</phone>
    <phone_ext>+86</phone_ext>
    <email>zhangxxi@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ruihao huang, MD</last_name>
    <phone>18984398751</phone>
    <phone_ext>+86</phone_ext>
    <email>1169731117@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Xinqiao Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xi Zhang, MD/PhD</last_name>
      <phone>13808310064</phone>
      <phone_ext>+86</phone_ext>
      <email>zhangxxi@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Ruihao Huang, PhD candidate</last_name>
      <phone>18984398751</phone>
      <phone_ext>+86</phone_ext>
      <email>1169731117@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Xi Zhang, MD</investigator_full_name>
    <investigator_title>chef of hemotology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

